Highest-materiality recent filing
Elected Mace Rothenberg, M.D. (5,982,651 for, 1,107,751 withheld) and David J. Woodhouse (7,087,293 for, 3,109 withheld) as Class II directors.
Surrozen Q1 2026 net loss $127.5M; cash $106.9M; on track for SZN-8141 IND in H2 2026
Net loss $127.5M ($11.65/sh) vs $27.0M ($7.43/sh) in Q1 2025, driven by non-cash fair value changes on warrants and tranche liability.
Surrozen reports FY2025 net loss $242M; cash $89.2M; expects IND for SZN-8141 in H2 2026
Cash and equivalents $89.2M at Dec 31, 2025, up from $34.6M year-end 2024; additional $30.2M raised in early 2026 via ATM and warrant exercises.
Director Shao-Lee Lin resigns from Surrozen board effective immediately
Shao-Lee Lin, M.D., Ph.D., resigned from the Board on January 26, 2026, effective immediately.
Surrozen Q3 net loss $71.6M, appoints new CFO
Net loss $71.6M ($8.36/diluted share) vs $1.4M ($0.44) YoY; driven by $40.7M non-cash tranche liability loss and $20.9M other expense.
Surrozen's collaboration agreement terminated by TCGFB for convenience, effective Nov 13
TCGFB terminated Collaboration Agreement for convenience; no termination penalties incurred by either party.
Surrozen enters ATM equity offering agreement for up to $50M with TD Cowen
Sales Agreement with TD Securities (USA) LLC to sell up to $50M of common stock at-the-market or in negotiated transactions.
Surrozen Q2 2025 net income $39.7M on non-cash gains; cash $90.4M, appoints new clinical VP
Net income of $39.7M ($2.55/diluted share) versus net loss of $25.3M in Q2 2024; driven by non-cash gains on tranche liability and warrant revaluation.
Surrozen stockholders elect three Class I directors and ratify Ernst & Young as auditor
Anna Berkenblit, M.D. elected with 1,351,951 for, 503,791 withheld, 453,045 broker non-votes.
Surrozen Q1 net loss $27M, cash $101.6M; discontinues SZN-043, pivots to ophthalmology
Net loss of $27.0M ($7.43 per share) vs $8.8M ($4.24 per share) in Q1 2024; R&D expenses $6.6M.
Surrozen reports FY2024 net loss of $63.6M; secures $76.4M financing for ophthalmology pipeline
Net loss $63.6M for 2024 vs $43.0M in 2023; Q4 net loss $28.0M.
Surrozen raises ~$76.4M in first tranche private placement; appoints Tim Kutzkey to Board
First tranche closed March 26, 2025; gross proceeds ~$76.4M from 6,586,415 Units at $11.60 each.
Surrozen secures $175M PIPE for ophthalmology Wnt mimetics, drops liver program
Oversubscribed $175M private placement (two tranches: $70M initial, $105M contingent on FDA clearance) led by Venrock Healthcare Capital Partners.
Surrozen reports Q3 net loss of $1.4M (vs $10.4M YoY); gets $10M BI milestone for SZN-413
Net loss narrowed to $1.4M from $10.4M in Q3 2023; collaboration revenue $10.0M (BI milestone).
Surrozen extends HQ lease through April 2029 with escalating rent, $400K early termination option
Lease term extended 48 months to April 2029; annual base rent starts at $2.3M, rises to $2.6M.
Surrozen Q2 net loss widens to $25.3M on $20.4M warrant loss; cash at $37.8M
Cash and cash equivalents $37.8M as of June 30, 2024, up from $27.3M at March 31, 2024.
Surrozen director Tim Kutzkey resigns from board and committees effective June 30
Tim Kutzkey, Ph.D. resigned as director and from all board committees on June 30, 2024.
Surrozen reports 2024 annual meeting vote results: directors elected, auditor ratified
Three Class III directors elected: Christopher Y. Chai, Mary Haak-Frendscho, and Craig Parker.
Surrozen Q1 net loss $8.8M; cash $27.3M; SZN-043 Phase 1b enrollment starts Q2 2024
Cash $27.3M at Mar 31; proforma $43.2M after April financing. Net loss $8.8M vs $14.3M YoY.
Surrozen raises $17.5M in private placement with milestone-triggered warrants
Issues 1,089,033 shares at $15.50 and pre-funded warrants for 40,000 shares at $15.4999.
Phase 1a enrolled 48 subjects (40 healthy, 8 cirrhotic); doses 0.5-3 mg/kg IV; no serious adverse events.
Upon the recommendation of the Nominating and Corporate Governance Committee, on March 26, 2025, Tim Kutzkey, Ph.D., was appointed to serve as a Class I director of the Company’s Board of Directors
On June 30, 2024, Tim Kutzkey, Ph.D. notified Surrozen, Inc. of his resignation as a member of our board of directors and from all committees of the board of directors on which he served, effective as of June 30, 2024.
Max materiality 0.80 · Median 0.65 · Most common event earnings